Pediculosis Capitis

• FDA approval · 2021-05-28
  FDA Approved: SKLICE — Supplemental Application (Azurity Pharmaceuticals)

  The FDA approved a supplemental application for SKLICE (ivermectin), manufactured by Azurity Pharmaceuticals.

• FDA approval · 2020-10-27
  FDA Approved: SKLICE — Supplemental Application (Azurity Pharmaceuticals)

  FDA approved a supplemental application for SKLICE (ivermectin) by Azurity Pharmaceuticals to authorize changes related to the product's use…

• FDA approval · 2017-06-16
  FDA Approved: SKLICE — Supplemental Application (Azurity Pharmaceuticals)

  The FDA approved a supplemental application for SKLICE (ivermectin) submitted by Azurity Pharmaceuticals.

• FDA approval · 2014-12-30
  FDA Approved: NATROBA — Supplemental Application (Cipher Pharmaceuticals Inc.)

  The FDA approved a supplemental application for NATROBA (spinosad) filed by Cipher Pharmaceuticals Inc., updating the labeling for the exist…

• FDA approval · 2012-05-23
  FDA Approved: OVIDE — Original Application (Taro Pharmaceuticals U.S.A., Inc.)

  FDA approved the original application for OVIDE, a topical malathion lotion for head lice infestation.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2012-02-07
  FDA Approved: SKLICE — Original Application (Azurity Pharmaceuticals)

  FDA approved SKLICE (ivermectin) via an Original Application NDA for topical treatment of head lice infestations in patients aged 6 months a…

• FDA approval · 2011-01-18
  FDA Approved: NATROBA — Original Application (Cipher Pharmaceuticals Inc.)

  FDA approved NATROBA (spinosad) from Cipher Pharmaceuticals as an original NDA for treating head lice infestation (pediculosis capitis).